PV has an incidence of three cases per 100,000 in adults but is very rarely seen in children, with fewer than 0.1% of PV patients diagnosed before 20 years of age. PV in children is far more often the result of congenital or acquired causes of an increased red blood cell mass. These include primary familial polycythemia (characterized by specific mutations in the erythropoietic receptor gene) and secondary polycythemias caused by abnormal hemoglobins, cardiac and pulmonary disease, excessive erythropoietin, and a relative polycythemia that is the result of decreased plasma volume.
PV in children and adults is associated with clonal hematopoiesis, JAK2 V617F mutations (in 95% of patients; with mutations in JAK2 exon 12 representing 2% to 4%), overexpression of PVR-1 RNA, and endogenous erythroid colony growth. In contrast to adults, children with PV may be less likely to have JAK2 V617F mutations and endogenous erythroid colony growth, such that the proposed revision to WHOs diagnostic criteria, may be less helpful in the diagnosis of PV in children, although other reports suggest that the proposed WHO criteria are equally applicable to children. The proposed criteria include: (1) a hemoglobin >16.5 g/dL in men or >16.0 g/dL in women; (2) a BM biopsy showing trilineage myeloproliferation and pleomorphic megakaryocytes; and (3) either a JAK2 mutation or a serum erythropoietin level below the normal reference range. Although the pathogenesis is currently unclear, patients also have abnormalities in tissue factor, endogenous anticoagulants mechanisms, hyperhomocysteinemia, and acquired von Willebrand syndrome.
Children with PV may present with signs and symptoms associated with an increased red blood cell mass such as headache, dizziness, fatigue, pruritus, night sweats, and a ruddy complexion. Mild splenomegaly may be present, but massive hepatosplenomegaly is rare. As a result of hyperviscosity of the blood, elevated platelet counts, and coagulation abnormalities, patients can develop thromboses and CNS ischemia, although the incidence of thrombotic events may be lower than that reported in adults.
Many different agents have been used to treat patients with PV, including chlorambucil, melphalan, 6-thioguanine, uracil mustard, busulfan, carboquone, anagrelide, imatinib, hydroxyurea, radioactive phosphorous, and IFN. Despite these efforts, the best approach to patients with PV remains unclear. Therefore, the British Committee for Standards in Haematology formulated recommendations for the initial management of PV. Recommendations include phlebotomy to maintain a hematocrit level second choice. However, the JAK inhibitor ruxolitinib was recently found to have excellent results in controlling the hematocrit and splenomegaly with minimal side-effects in an open-label phase III trial. This may eventually supplant IFN and hydroxyurea as front-line therapy once pediatric-specific dosing is available. Finally, allogeneic transplantation has been successfully used to treat some adult patients with PV, especially those with progression to myelofibrosis or AML. Younger patients, and those with matched related donors, did especially well, suggesting that allogeneic transplant should be considered in pediatric patients with PV, though data is currently limited to case reports.